Janssen: New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) in Treatment of Heavily Pre-treated Patients with Multiple Myeloma

Data presented at ASH 2021 congress show 83 percent of patients achieved a stringent complete response at median follow-up of 22 months1 92 percent of evaluable patients achieved minimal residual

Related Keywords

China ,United States ,Chinese ,American ,Ciltacabtagene Autoleucel ,Noah Reymond ,Edmond Chan Mbch ,Thomas Martin ,Sen Zhuang ,Jessica Moore ,Myeloma Program ,Janssen Biotech Inc ,American Society Of Clinical Oncology ,American Society Of Hematology Annual Meeting ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,American Society Of Hematology ,Clinical Research ,American Cancer Society ,None Of The Janssen Pharmaceutical Companies ,Bone Marrow Transplantation Program ,Drug Administration ,International Staging System ,Exchange Commission ,Companies Of Johnson ,European Medicines Agency ,European Medicines Agency Seeking Approval ,Hematopoietic Malignancies Program ,Johnson ,Helen Diller Family Comprehensive Cancer Center ,American Society ,Clinical Oncology ,Annual Meeting ,Confidence Interval ,Clinical Professor ,Adult Leukemia ,Associate Director ,Diller Family Comprehensive Cancer Center ,Vice President ,Edmond Chan ,Area Lead Haematology ,Janssen Biotech ,Legend Biotech ,Marketing Authorisation Application ,Biologics License Application ,Therapy Designation ,European Commission ,Breakthrough Therapy Designation ,Orphan Drug Designation ,Multiple Myeloma ,Pharmaceutical Companies ,Cardiovascular Metabolism ,Infectious Diseases Vaccines ,Janssen Cilag Limited ,Concerning Forward Looking Statements ,Private Securities Litigation Reform Act ,Janssen Pharmaceutical ,Annual Report ,Note Regarding Forward Looking ,Quarterly Report ,Results From ,Patients With ,Refractory Multiple ,Annual Meeting Exposition ,Hematology Annual ,Refractory Multiple Myeloma ,Chimeric Antigen Receptort Cell ,Participants With Relapsed ,Janssen Enters Worldwide Collaboration ,License Agreement ,Chinese Company Legend Biotech ,Develop Investigational ,Submits Marketing Authorisation Application ,Initiates Rolling Submission ,Announces Investigational ,European Medicines ,Medicines Agency ,Today Population Factsheets ,Janssen ,Data ,Rom ,Artitude ,Study ,Show ,Ontinued ,Jeep ,Durable ,Responses ,Ciltacabtagene ,Utoleucel ,Kilta ,Treatment ,Heavily ,Reated ,Patients ,Multiple ,Myeloma ,